title: Ex vivo 1H and 31P magnetic resonance spectroscopy as a means for tumor             characterization in ovarian cancer patients.
abstract: We aimed to determine whether cells obtained from malignant ovarian tumors             had different ex vivo 1H- and 31P (phosphorus-31)-magnetic resonance (MR) spectra             compared to cells obtained from benign ovarian cysts. In addition, we aimed to             assess the metabolic effects of chemotherapy on malignant cells obtained from             peritoneal effusions of ovarian cancer patients. We included 20 ovarian cancer             patients undergoing explorative laparotomy for tumor resection, 15 patients undergoing             oophorectomy for benign ovarian cysts and 8 patients with advanced ovarian cancer             with cancerous peritoneal effusion undergoing palliative percutaneous drainage.             Ovarian and metastatic tissues were obtained from all patients undergoing laparotomy             and analyzed using 1H magnetic resonance spectroscopy (MRS). Cancerous cells from             peritoneal effusions were incubated with 3 different anti-mitotic drugs (paclitaxel,             cisplatin and carboplatin) at LC50 and the consequent metabolic changes were monitored             using 31P-MRS. 1H-MRS revealed significantly higher intracellular lactate levels             in cells obtained from ovarian tumors, most prominently in the moderately to poorly             differentiated histological types, while total choline (Chol) compounds were higher             in the moderately to poorly differentiated subgroup only. Ovarian cancer cells             obtained from peritoneal effusions showed a significantly decreased glycerophosphocholine             (GPC), glycerophosphoethanolamine (GPE) and uridine diphospho-sugar (UDPS) levels             following ex vivo exposure to all 3 anti-mitotic drugs. Ex vivo 1H-MRS identified             significant metabolic differences between cells obtained from ovarian tumors compared             to those originating in benign ovarian cysts, including increased lactate and             total choline compound levels. The 31P-MRS technique allowed characterization             and monitoring of metabolic changes occurring in ovarian cancer cells in response             to chemotherapy.
authors.affiliation: Department of Obstetrics and Gynecology, Carmel Medical Center, Technion University, Rappaport Faculty of Medicine, Haifa, Israel. yabramov@012.net.il
authors.forename: Yoram
authors.initials: Y
authors.lastname: Abramov
authors.forename: Shani
authors.initials: S
authors.lastname: Carmi
authors.forename: Shaoul O
authors.initials: SO
authors.lastname: Anteby
authors.forename: Israel
authors.initials: I
authors.lastname: Ringel
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000188:drug therapy / Q000473:pathology*; D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy / Q000473:pathology*; D000368:Aged; D050256:Antimitotic Agents / Q000494:pharmacology; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy / Q000473:pathology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006859:Hydrogen; D009682:Magnetic Resonance Spectroscopy; D008875:Middle Aged; D008938:Mitosis / Q000187:drug effects; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000473:pathology*; D009367:Neoplasm Staging; D010048:Ovarian Cysts / Q000188:drug therapy / Q000473:pathology*; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000473:pathology*; D010758:Phosphorus; D011379:Prognosis
chemical_list: D050256:Antimitotic Agents; D010758:Phosphorus; D006859:Hydrogen